secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001193125-24-147093
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics stockholders elect David Kirn as Class I director and ratify PwC as auditor
--------------------------------------------------------------------------------

- David Kirn, M.D. elected as Class I director with 35,630,613 votes for, 7,849,441 withheld, and 1,574,659 broker non-votes.
- Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2024: 45,032,000 for, 21,052 against, 1,661 abstain.
- Annual Meeting held on May 21, 2024; 45,054,713 of 51,157,472 outstanding shares voted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524147093/0001193125-24-147093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312524147093/d649174d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-147093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer